Cosmetic cross-reference Noindex: medium evidence

Lyral

CAS 31906-04-4

Lyral (CAS 31906-04-4) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed

Label records

0

SOURCE EMBL-EBI ChEMBL

Bioactivity

0

SOURCE DrugCentral

Adverse signals

0

SOURCE IUPHAR/BPS

PubMed IDs

0

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Lyral

CAS Number

31906-04-4

UNII

QUE43B9Z2Q

InChIKey

ORMHZBNNECIKOH-UHFFFAOYSA-N

ChEMBL ID

CHEMBL3182066

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Lyral used for in pharmaceutical contexts?

Lyral (CAS 31906-04-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Lyral?

No adverse-event association or SIDER side-effect rows are rendered for Lyral in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Lyral also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for HICC (Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde) with EU status "restricted".

What clinical phase is Lyral in?

No phase 1-4 clinical development badge is rendered for Lyral because the matched compound identifier rows do not contain a max-phase value.